Loading

Genomic Expression

June 16, 2025
Company Presentation
Other
RNA AI Platform for Next Generation Cures - because by analyzing RNA, we can detect disease, monitor health, and design the Next Generation Cures RNA is the cell software, and by decoding it, we can recode biology. Our RNA AI platform not only improves patient outcomes now but fundamentally shifts how we approach cancer treatment and drug discovery and development in the future - potentially bending the cost and time curve for new drug approvals. The Problem: Despite significant advancements in cancer treatment, the reality remains stark: 50-80% of patients do not benefit from standard of care, with drugs that are expensive to develop. Our Solution: OneRNA® Platform enables truly individualized treatment by accurately quantifying all RNAs in the sample, statistically powering the results, and connecting the dots to approved drugs that can interrogate the abnormally expressed genes or their product.
Genomic Expression
Company HQ City: Beverly
Company HQ State: MA
Company HQ Country: United States
Year Founded: 2017
Lead Product in Development: OneRNA Platform validated in breast and ovarian cancer

CEO

Gitte Pedersen

Year Founded

2017

Development Phase of Lead Product

Other/Not Applicable

Number of Unlicensed Products Looking for Licensing

1

When you expect your next catalyst update?

Launching of OneRNA® as a diagnostic platform and scaling revenue

What is your next catalyst (value inflection) update?

in 2025 Q3

Website

https://www.genomicexpression.com/
Primary Speaker
Gitte Pedersen
Gitte Pedersen, MSc
CEO
Genomic Expression Inc

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS